Press Releases

FF officially launched its robotics business in the Middle East last week and completed the sale and delivery of its first order in the region, delivering six robots in total—two humanoid robots and four quadruped robots. This marks FF EAI Robotics’ breakthrough from zero to one in the Middle East Region. On August 26, FF held Part One of its "Built in USA, Benefit the World," Launch Event and Global Business Partner Conference. At the event, FF launched the "EAI Robotics Made in USA" Global Industry Alliance Initiative and outlined the three-phase roadmap for its Acceleration Program. FF will hold Part Two of its Business Partner Conference on September 28. On September 19, FF will

TULSA, Okla., Aug. 30, 2026 /PRNewswire/ -- ONEOK, Inc. (NYSE:OKE) today announced the commencement of cash tender offers ("Tender Offers") to purchase up to an aggregate principal amount that will not result in an aggregate purchase price that exceeds $2 billion (subject to increase or decrease by ONEOK, the "Aggregate Maximum Tender Amount") of its outstanding debt securities of the 20 series listed in the table below (the "Notes" and, each series, a "series of Notes"), subject to the order of priority (the "Acceptance Priority Levels") as set forth in the table below under "Acceptance Priority Level." The Tender Offers form part of the previously-announced repayment plan to repurchase or

Acquisition Increases Momentum Toward the High End of ONEOK's Mid- to High-Single-Digit Adjusted EBITDA Growth Target Over the Next Five to Seven YearsExpected to Be Immediately Accretive to Earnings and Free Cash Flow Per Share$9 Billion Minority Equity Investment from ApolloFunds Acquisition and $5 Billion Debt ExtinguishmentAccelerates Deleveraging to 3.25x Debt-to-EBITDA with No Issuance of Common EquityAccelerates ONEOK's Flexibility for Capital Allocation Including Organic Growth, Potential Dividend Increases and Share BuybacksTULSA, Okla., Aug. 30, 2026 /PRNewswire/ -- ONEOK, Inc. (NYSE:OKE) today announced that it has executed a definitive agreement to acquire Brazos Midstream's Perm

OAKLAND, Calif., Aug. 30, 2026 /PRNewswire/ -- Pacific Gas and Electric Company (PG&E) today released a statement on Senate Bill 492. "On Saturday, the California Legislature amended Senate Bill 492 to address the state's wildfire risk reduction and recovery framework.While the proposed legislation would make some progress in helping wildfire survivors recover and strengthening wildfire preparedness, it would not provide the sustainable solution California needs.Specifically, the bill does not adequately address the financing risks created by California's current wildfire liability framework. As a result, it falls short of crea

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/dL at Month 12, and more than half achieved triglycerides below 150 mg/dL - - Plozasiran reduced cumulative acute pancreatitis (AP) events by 78% versus placebo in patients with TG above 500 mg/dL, with or without a prior history of AP - - Greater absolute benefit of AP risk reduction was observed in patients at higher risk - - In the highest-risk subgroup, patients with TG above 880 mg/dL and a prior history of AP, there was a 100% reduction in even

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysis - Patients treated with acoramidis were observed to have an unprecedented 65 additional days alive and out of the hospital by Month 36 versus baseline placebo patients - Acoramidis demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups, including p.Val142Ile and non-p.Val142Ile. These findings were simultaneously published in the European Journal of Heart Failure PALO ALTO,

L3Harris Technologies (NYSE:LHX) has contributed key elements to NASA’s successfully launched Nancy Grace Roman Space Telescope, an observatory designed to map the universe. The milestone also marks the culmination of more than a decade of engineering, innovation and collaboration between L3Harris and NASA’s Goddard Space Flight Center. L3Harris provided the 2.4-meter Optical Telescope Assembly (OTA) for NASA, which serves as Roman’s eye. The company also supported the mission with radiation-hardened electronics, which keep the telescope in operation approximately 1 million miles from Earth. "It’s a great source of pride for L3Harris that the optical eye we engineered will survey the co

– Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline – – Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM – – Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes – – New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the le

SINGAPORE, Aug. 29, 2026 (GLOBE NEWSWIRE) -- ChowChow Cloud International Holdings Limited ("Chowchow", the "Company") (NYSE:CHOW) announced today that the Company had become aware of unusual trading activity in its ordinary shares on the NYSE American LLC (the "NYSE American") on August 12, 2026 and August 27, 2026. The Company is issuing this press release pursuant to Section 401(d) of the NYSE American Company Guide. The Company has made inquiries and has been unable to determine whether corrective actions are appropriate at this time. The Company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge,

New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic obstructive hypertrop

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the Eu

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo With full statistics analysis now complete, Company confirms TNX-103’s biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecting increased cardiac wall stress. Results will inform protocol population enrichment and changes to overall registrational path CHAPEL HILL, N.C., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeu

Destiny Tech100 Inc. (NYSE:DXYZ) today announced financial results for the quarter ended June 30, 2026. The fund reported a net asset value (NAV) of $34.30 per share of common stock, up from $24.56 per share at the end of the first quarter of 2026.As of June 30, 2026, Destiny Tech100’s investment portfolio had an aggregate fair value of approximately $1.64 billion, including short-term investments. The fund maintains positions in a variety of privately-held technology companies.Additional InformationFor more information about the Tech100, DX Advisors LLC, the fund’s investment adviser, has made extensive resources available on the fund website. Prospective investors and the general public ar

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve Fatigue Approval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda ((TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View

CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 28, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its previously announced investor webinar on Wednesday, September 2, 2026 has been

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE:UTF) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal year-to-date. In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE:FOF) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal year-to-date. In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term cap

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal year-to-date. In December 2012, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term cap

- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia™ patent portfolio expands to nine granted U.S. and European patents - Company issues update on Nasdaq listing DUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today provided an update on key developments across its diagnostics business, highlighting continued commercial progress, operational transformation and diagnostic pipeline advancement. Strengthening Commercial Leadership in Europe Trinity Biotech is pleased to announce that Jordi Rom

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal year-to-date. In December 2011, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capit